



**Food and Drug Administration Advisory Committee Member  
Acknowledgment of Financial Interests**

Name of Advisory Committee Temporary Member’s Name: Dr. James Hildreth

Committee: Vaccines and Related Products Advisory Committee (VRBPAC)

Meeting Date: June 14-15, 2022

I acknowledge that contingent upon public disclosure of the following financial interest(s) related to the meeting topic: The committee will meet in open session to discuss recent requests to amend the Emergency Use Authorization (EUA) of the Moderna COVID-19 mRNA vaccine to include the administration of a primary series to infants, children, and adolescents 6 months through 17 years of age, and also to amend the EUA of the Pfizer-BioNTech COVID-19 mRNA vaccine to include the administration of a primary series to infants and children 6 months through 4 years of age. I may be considered for participation in the advisory committee meeting described above.

<u>Type of Interest</u>	<u>Nature</u>	<u>Magnitude</u>
<b>I. Personal/Immediate Family</b>		
Clinical Trial Participation	Affected Firm	\$0 - \$5,000
<b>II. Other Imputed Interests</b>		
Vaccine Test Site; Meharry Medical College	(b) (4) and NIH/NIAID, Affected Firms	\$1,500,000 - \$2,000,000
Vaccine Test Site; Meharry Medical College	Moderna, Affected Firm	\$400,000 - \$600,000

I hereby request that FDA make this information publicly available on my behalf if the agency grants a waiver allowing me to participate in the meeting described above. I understand that without public disclosure of these interests, I will not participate in the advisory committee meeting described above.

\_\_\_\_\_- S-\_\_\_\_\_  
Signature  
James Hildreth, M.D., Ph.D.

\_\_\_\_\_  
Date 6-6-2022